Sentences with phrase «cell treatments causing»

There have been a handful of cases of stem cell treatments causing growths but this appears to be the first in which the treatment was given at a Western hospital as part of an approved clinical trial.

Not exact matches

CAR - T treatments, including competing products from Novartis rivals Kite Pharma and Juno Therapeutics, come with the risk of potentially deadly side effects such as cytokine - release syndrome (CRS), in which a glut of T - cell - assisting cytokines can cause high fever, low blood pressure, and problems with lung oxygenation.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

The triggering of PARP enables cancer cells to withstand anti-hormone therapy treatment, causing cells to cultivate and develop into a more aggressive form.

Following the dose, the activity of caspase — an «executioner» enzyme that causes cells to self destruct — increased by between 120 and 720 per cent, confirming that people respond differently to treatment.

As a result, P - gp causes resistance of the diseased cells to a majority of drugs currently available for the treatment of cancer, as well as drugs used for treatment of infectious diseases like HIV / AIDS.

Conventional, high - dose chemotherapy treatments can cause the fibroblast cells surrounding tumors to secrete proteins that promote the tumors» recurrence in more aggressive forms, researchers at Taipei Medical University and the National Institute of Cancer Research in Taiwan and University of California, San Francisco, have discovered.

Cancer stem - like cells are thought to be the root cause of chemotherapy resistance, leading to treatment failure in patients with advanced disease and the triggers of tumour recurrence and metastasis (regrowth).

While gold nanospheres, without any accompanying drug, were found to cause significant cell damage, treatment - resistant cell populations did eventually recover several days after the radiotherapy.

Professor Rudi Beyaert (VIB / UGent): «We found that pharmacological treatment of human skin cells with drugs that inhibit the activity of MALT1 reduced the production of inflammation promoting proteins caused by mutant variants of CARD14.

In their experimental treatment, he and his colleagues injected mice, ferrets, and monkeys with viral DNA, causing their muscle cells to produce hemagglutinin, a protein found on the surface of all flu viruses.

In the mice, drug treatment caused a shutdown of excess protein production in myc - driven cancer cells.

Researchers targeting colorectal cancer stem cells — the root cause of disease, resistance to treatment and relapse — have discovered a mechanism to mimic a virus and potentially trigger an immune response to fight the cancer like an infection.

Certain conditions affect one sex more than the other, he notes, so «if the genetics of a cell affects the progress of a disease, it might suggest specific causes or treatments for disease.»

But virus infections can cause cells to break open, leaking the toxin into the water and subsequently into water facility intake pipes and treatment centers.

However, she argues that the results are a breakthrough in cancer research as it may be the first step towards effective treatment of cancer stem cells, i.e. the cells believed to cause metastases.

«This is the first study to show the actual cell behaviors caused by mutations in genes causally linked to polycystic kidney disease, an important new step in the path towards treatment,» said Dr. Robert L. Bacallao, associate professor of medicine at the IU School of Medicine in Indianapolis.

These vulnerable patients, whose immune defenses have taken a dramatic double hit from both their original disease and the treatments required to repopulate their immune system with donor cells, are especially susceptible to a wide range of infections that typically don't cause major problems in healthy people.

The experiments reveal that the sudden loss of energy supply to the heart cells and the subsequent rapid «reboot» during treatment causes mitochondria to falter and trigger a whirlwind of aberrant electrical signals.

Cancer stem cells, a type of self - renewing cell found in tumors, are of particular interest because they are the main cell type responsible for tumor progression and for resistance to chemotherapy and radiotherapy, and therefore a major cause of tumor recurrence after treatment.

Dr Gillian Farnie, whose work at the University's Institute of Cancer Sciences was funded by a five - year # 500,000 Breast Cancer Campaign Scientific Fellowship, said: «We know that cancer stem cells are able to avoid or repair damage caused by treatment.

The treatment — a whole - body graft of genetically modified stem cells — is the most ambitious attempt yet to treat a severe form of epidermolysis bullosa (EB), an often - fatal group of conditions that cause skin to blister and tear off at the slightest touch.

«In this exciting new study, the authors provide support for a new experimental treatment approach that works by helping nerve cells digest toxic proteins that might otherwise cause cell death,» said John Krystal, Editor of Biological Psychiatry.

This work highlights the fact that most psoriasis treatments do not kill these disease causing T cells but instead temporarily suppress their activation.

According to Prof. Shaked, the drug caused inflammatory cells (macrophages) in the bone marrow to enhance the aggressiveness of the disease and provide the cancer cells with resistance to treatment.

But stem cells are slower paced, which means that mutant versions — which might give rise to a variety of tumor - causing cells — could survive the treatment.

The drug treatment and radiation cause damage to the epithelial cells, which form part of the intestinal mucosal layer.

Published May 4, 2015, in Nature Neuroscience, the new findings may eventually lead to treatment strategies targeted for the underlying causes of schizophrenia and related disorders, said the study's corresponding author Scott Soderling, an associate professor of cell biology and neurobiology in the Duke School of Medicine.

Importantly, the antibody treatment also caused severe degeneration of nerve cell dendrites, the regions that are essential for normal communication between nerve cells.

The researchers anticipate that the pigs could be a practical way to test treatments for HD, which is caused by a gene encoding a toxic protein that causes brain cells to die.

Ozone treatment caused no changes in the PLGA and no loss of function, with cells still able to grow on the polymer scaffold, as they would in treatments.

Dr Bernardo Tavora, lead author on the paper from the Barts Cancer Institute, said: «This work shows that sensitivity to cancer treatment is related to our own body mistakenly trying to shield the cancer from cell - killing effects caused by radiotherapy and chemotherapy.

But then those cells swarmed, clustered and jammed up the blood vessels causing a potentially dangerous blockage, and that was a revelation, one that could lead to new treatment options for the usually deadly incursions.

However, such molecular treatments reproducibly cause rapid loss of many circulating blood cells, as macrophages now attack some healthy cells as well.

A new drug that targets not only common cancer - causing genetic mutations in patients with non-small cell lung cancer (NSCLC), but also a form of the mutation that causes resistance to treatment, has shown promising results in patients in a phase I / II clinical trial.

They are hypothesized to be the cells that undergo cancerous transformation and cause Merkel cell carcinoma, an aggressive form of skin cancer with no effective treatment.

The method, successfully tested in heart muscle cells from patients, offers an efficient alternative to the daunting task of developing an individualized molecular treatment for each gene mutation that causes DMD.

The study could inform new treatments for a set of conditions known as peripheral neuropathies, which are caused by damage to the cells in the PNS and can lead to extreme sensitivity to touch as well as numbness and muscle weakness.

- In a study with potentially major implications for the future treatment of autoimmunity and related conditions, scientists from the Perelman School of Medicine at the University of Pennsylvania have found a way to remove the subset of antibody - making cells that cause an autoimmune disease, without harming the rest of the immune system.

This treatment resistance may be caused by certain anti-NMDA receptor antibody - producing plasma cells that remain inaccessible to current immunotherapies.

As part of the long effort to improve treatment of tuberculosis (TB), microbiologists led by Yasu Morita at the University of Massachusetts Amherst report that they have for the first time characterized a protein involved in making a glycolipid compound found in the TB cell wall, which is critical for the disease - causing Mycobacterium to become infectious.

What is clear so far is that the treatment at least causes no harm to people treated with their own or donor cells for a range of disorders, according to pilot studies by Kurtzberg and others.

It doesn't kill the cell that it hides in, but is dangerous enough that it can cause infections in individuals with an impaired immune system, such as patients who are receiving cancer treatment, who have pre-existing lung problems or whose immune systems are otherwise compromised.

Aggressor cells, which have the potential to cause autoimmunity, are targeted by treatment, causing conversion of these cells to protector cells.

The fact that Connexin 30 knockout mice had a higher number of grafted cells than normal mice, and that some of the grafted cells expressed CONNEXIN 30 is a very important finding when considering cell transplantation as a treatment for hereditary hearing loss caused by CONNEXIN deficiency.

In laboratory experiments, researchers at Karolinska Institutet in Sweden demonstrate that estrogen treatment and overexpression of the estrogen receptor cause malignant neuroblastoma cells to mature into neuron - like cells.

The results from the study showed neoadjuvant anti-PD-1 treatment could enhance the priming of anti-tumor T - cells, potentially eliminating micro-metastatic cancer that can cause post-surgical relapse.

LONDON — Wellcome Trust, the United Kingdom's largest biomedical research charity, today announced more than # 4 million in support for a pioneering, and potentially controversial, IVF treatment that could prevent some forms of muscular dystrophy and other diseases caused by defective mitochondria, the energy - generating organelle in cells.

One treatment is a vaccine that targets a structure on the outside of cancer cells, while the other is an altered enzyme that breaks apart RNA and causes the cell to commit suicide.

Older traditional treatments that included interferon and ribavirin were less effective and caused a variety of side effects, including fatigue, as well as flu - like symptoms, depression and lowered blood cell counts.